Cargando…
Generating Inhibitors of P-Glycoprotein: Where to, Now?
The prominent role for the drug efflux pump ABCB1 (P-glycoprotein) in mediating resistance to chemotherapy was first suggested in 1976 and sparked an incredible drive to restore the efficacy of anticancer drugs. Achieving this goal seemed inevitable in 1982 when a series of calcium channel blockers...
Autores principales: | Crowley, Emily, McDevitt, Christopher A., Callaghan, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121335/ https://www.ncbi.nlm.nih.gov/pubmed/19949934 http://dx.doi.org/10.1007/978-1-60761-416-6_18 |
Ejemplares similares
-
Aromatase inhibitors--where are we now?
por: Miller, W. R.
Publicado: (1996) -
Lysine methyltransferase inhibitors: where we are now
por: Feoli, Alessandra, et al.
Publicado: (2021) -
Angiogenesis inhibitors in clinical development; where are we now and where are we going?
por: Eskens, F A L M
Publicado: (2004) -
Editorial: Antipsychotics of New Generation: Where Are We now?
por: Lipina, Tatiana V., et al.
Publicado: (2021) -
Voices: Where are they now?
Publicado: (2023)